LLY

762

-0.13%↓

JNJ

175.33

-1.02%↓

ABBV

220.83

+0.35%↑

UNH

339.31

-0.35%↓

AZN

76.87

-1.06%↓

LLY

762

-0.13%↓

JNJ

175.33

-1.02%↓

ABBV

220.83

+0.35%↑

UNH

339.31

-0.35%↓

AZN

76.87

-1.06%↓

LLY

762

-0.13%↓

JNJ

175.33

-1.02%↓

ABBV

220.83

+0.35%↑

UNH

339.31

-0.35%↓

AZN

76.87

-1.06%↓

LLY

762

-0.13%↓

JNJ

175.33

-1.02%↓

ABBV

220.83

+0.35%↑

UNH

339.31

-0.35%↓

AZN

76.87

-1.06%↓

LLY

762

-0.13%↓

JNJ

175.33

-1.02%↓

ABBV

220.83

+0.35%↑

UNH

339.31

-0.35%↓

AZN

76.87

-1.06%↓

Home・Listă Acțiuni・Minerva Neurosciences Inc

Minerva Neurosciences Inc

Deschisă

2.08 0.48

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.9

Maxim

2.2

Indicatori cheie
By Trading Economics
P/E Medie Sector	1.444 35.293
EPS	-0.43
Angajați	8

Dividende
By Dow Jones
Următoarele câștiguri	3 nov. 2025

Statistici piață
By TradingEconomics
Capitalizare de piață	4M 14M
Deschiderea anterioară	1.6
Închiderea anterioară	2.08

Minerva Neurosciences Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 sept. 2025, 23:01 UTC

Achiziții, Fuziuni, Preluări

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 sept. 2025, 22:48 UTC

Achiziții, Fuziuni, Preluări

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 sept. 2025, 21:59 UTC

Câștiguri

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 sept. 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17 sept. 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 sept. 2025, 22:20 UTC

Achiziții, Fuziuni, Preluări

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 sept. 2025, 22:20 UTC

Achiziții, Fuziuni, Preluări

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 sept. 2025, 22:20 UTC

Achiziții, Fuziuni, Preluări

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 sept. 2025, 22:19 UTC

Achiziții, Fuziuni, Preluări

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 sept. 2025, 22:18 UTC

Achiziții, Fuziuni, Preluări

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 sept. 2025, 21:00 UTC

Câștiguri

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 sept. 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 sept. 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 sept. 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 sept. 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 sept. 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 sept. 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 sept. 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 sept. 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 sept. 2025, 17:15 UTC

Achiziții, Fuziuni, Preluări

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 sept. 2025, 17:06 UTC

Achiziții, Fuziuni, Preluări

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 sept. 2025, 16:51 UTC

Câștiguri

Correct: Exor 1H Net Loss -EUR624M

17 sept. 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 sept. 2025, 16:25 UTC

Câștiguri

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 sept. 2025, 16:23 UTC

Câștiguri

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Comparație

Modificare preț

Minerva Neurosciences Inc Așteptări

Consens privind evaluarea

By TipRanks

0 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 0 analiști care au acordat evaluări ale acțiunilor Minerva Neurosciences Inc - Dist în ultimele 3 luni.

Date financiare

Despre Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.